![]() |
|
Patient Information This information is Part 3 of a three-part “Product Monograph” published when GLUMETZA was approved for sale in Canada and is designed specifically for consumers. The following information is a summary for consumers and will not tell you everything about GLUMETZA. Contact your doctor or pharmacist if you have any questions about the drug. ABOUT THIS MEDICATION: What it does: GLUMETZA (metformin hydrochloride) extended-release tablets work to control your blood sugar by:
When it should not be used: Do not use GLUMETZA if:
What the medicinal ingredient is: Each tablet contains 500 mg or 1000 mg metformin hydrochloride What the important non-medicinal ingredients are: GLUMETZA 500 mg: hypromellose, microcrystalline cellulose, magnesium stearate, polyethylene glycol, polyethylene oxide, polysorbate, titanium dioxide. GLUMETZA 1000 mg: colloidal silicon dioxide, crospovidone, glyceryl behenate, polyvinyl alcohol, polyacrylate dispersion, hypromellose, talc, polyethylene glycol, titanium dioxide, simethicone emulsion, polysorbate, shellac glaze, iron oxide black, macrogol, n-butyl alcohol, propylene glycol, FD&C blue #2, FD&C yellow #6 and FD&C red #40.
What dosage forms it comes in: Extended Release tablets: Each tablet contains 500 mg or 1000 mg metformin hydrochloride.
INTERACTIONS WITH THIS MEDICATION: Always inform your doctor or pharmacist of all prescription over-the-counter, and herbal medicines that you are taking. Medicines which may require additional monitoring of your dose or condition include:
Interactions with herbal products have not been established. PROPER USE OF THIS MEDICATION: Follow the directions provided by your doctor for using this medicine. Only take this medicine with food, and drink plenty of fluids while taking this medicine. Do not miss any doses. Swallow whole. Do not break or crush tablets. Usual dose: Initial dose is 1000 mg with evening meal. Maximum daily dose is 2000 mg. Overdose: If an overdose is suspected, contact your local poison control centre or emergency immediately. Symptoms of overdose may include rapid breathing or trouble in breathing, nausea and vomiting followed by diarrhea, drowsiness, weakness, dizziness, and headache. Missed Dose: If a dose of this medication has been missed it should be taken as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to the regular dosing schedule. Do not double doses. If you do not feel well or your home glucose test shows higher levels, contact your physician. SIDE EFFECTS AND WHAT TO DO ABOUT THEM: Some possible side effects include diarrhea, nausea and stomach upset. If they continue or are bothersome, check with your doctor. After you are on the same dose for several days or weeks, if any of these symptoms come back, tell your doctor immediately. A late recurrence of stomach symptoms may be due to a serious medical condition (lactic acidosis). Remember, your doctor or other healthcare professional is the best source of information regarding you and your health. Please consult with your doctor or other healthcare professional if you have any questions about your health or medication. This is not a complete list of side effects. For any unexpected effects while taking GLUMETZA contact your doctor or pharmacist.
HOW TO STORE IT: This medicine should be stored at room temperature (15-30ºC). Keep out of reach of children. REPORTING SUSPECTED SIDE EFFECTS: To monitor drug safety, Health Canada collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Health Canada by: Toll-free telephone: 866-234-2345 Toll-free fax: 866-678-6789 By email: cadrmp@hc-sc.gc.ca National AR Centre NOTE: Before contacting Health Canada, you should contact your physician or pharmacist. MORE INORMATION: This document plus the full product monograph,
prepared for health professionals can be found at http://www.biovail.com or by
contacting the sponsor, Biovail Pharmaceuticals Canada, at 1 866 825-8120 or via
e-mail at MedInfo@Biovail.com. |
|
|||||||||||||||||||||||||||||||||||||||||||
| © 2007 Biovail Corporation - All Rights Reserved (BIO113B0602) | Privacy Policy | Disclaimers |